Exchange: NASDAQ·Updated 12:24 PM EDT
DMAC logo

DMAC DiaMedica Therapeutics Inc

$6.70
$0.04
(0.59%)
Today
Reported EarningsAug 10
Mkt Cap$363.46M
Vol46,592.00

About DMAC

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on preeclampsia, fetal growth restriction, and acute ischemic stroke. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases.
45

Neutral Sentiment

How do you feel about DMAC?

Advertisement|Remove ads.